Personalis (PSNL) Registration Filing summary

Company overview and business model

• Develops, markets, and sells advanced cancer genomic tests and services for pharmaceutical research, biomarker discovery, personalized cancer therapies, and clinical trial enrollment.

• Offers tests for physicians to detect residual or recurrent cancer, monitor therapy response, and guide therapy selection.

• Provides whole exome and genome sequencing services for diagnostic companies and population sequencing initiatives.

• Incorporated in Delaware in 2011; principal offices in Fremont, California.

• Qualifies as a “smaller reporting company” and utilizes scaled-back SEC disclosure requirements.

Financial performance and metrics

• Issued 14,044,943 shares at $3.56 per share in a private placement, raising approximately $50 million in gross proceeds.

• 88,263,269 shares of common stock outstanding as of February 21, 2025, including shares offered in this prospectus.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders.

• Bears registration and related expenses; selling stockholders responsible for commissions and transfer taxes.